T1	Participants 58 84	myelodysplastic disorders.
T2	Participants 229 274	patients with myelodysplastic syndromes (MDS)
T3	Participants 276 331	Sixty-eight evaluable patients with MDS were randomized
T4	Participants 1293 1310	patients with MDS
